Market Intelligence, Clinical Progress, and High-Purity Reagents for Migraine & CNS Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HTR1D drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | HTR1D Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell lines. CMV promoter, Puro selection. Sequence Verified. |
View HTR1D Products |
| Antigen / Membrane | HTR1D Membrane Extracts / ECD-Fc Fusion Protein Native conformation preserved. Extracellular domain (Met1-Asn195) expressed in HEK293, purity >95%, Endotoxin <1EU/μg. |
View HTR1D Products |
| Ortholog Panel | HTR1D Human/Mouse/Cynomolgus Comparison Set Sequence Verified orthologs for cross-species PK/PD bridging. |
View HTR1D Products |
| Benchmark Ab | Anti-HTR1D Reference Antibody Recombinant positive control for binding assays. |
View HTR1D Products |
| Validator | HTR1D siRNA Set For knockdown specificity verification. |
View HTR1D Products |
| Related Target: HTR1B | 5-HT1B Receptor (Close Homolog) Critical for selectivity screening (92% homology). |
View HTR1B Products |
| Related Target: HTR1F | 5-HT1F Receptor Alternative migraine target for comparative studies. |
View HTR1F Products |
| Related Target: CGRP Pathway | CALCA (ligand) & CALCRL (receptor component) Competitive pathway analysis for migraine therapeutics. |
View CALCA Products / View CALCRL Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity | Lentivirus for Stable Cell Lines preserving native membrane environment and glycosylation patterns (HEK293 derived) |
| HTR1B vs HTR1D Selectivity | Ortholog Panel with strict sequence verification; Human/Mouse/Cyno proteins available with theoretical MW confirmation |
| Calcium Flux & cAMP Modulation | Functional cell lines with Puromycin selection marker; validated for Gαi/o coupling detection |
| Brain Penetration Assessment | Cross-species epitope conservation analysis via sequence-aligned antigens |
| Lack of Reliable Controls | Recombinant Benchmark Antibodies included for binding assays |
| Off-Target False Positives | Validated siRNA included for specificity checks |
Key Genetic Variants: rs6299
The HTR1D gene harbors a known single nucleotide polymorphism, rs6299 (UniProt P28221 VAR_011834), resulting in a missense variant that may alter receptor function and drug response. This variant has implications for differential efficacy and safety of HTR1D-targeted therapeutics, especially in migraine and cluster headache populations. Understanding the impact of rs6299 on receptor conformation and signaling bias is crucial for developing personalized treatment strategies.
Global Clinical Landscape & Future Outlook
The HTR1D target has re-emerged as a critical node in migraine therapeutics, distinct from the historical 5-HT1B/1D mixed agonist approach (triptans). Current R&D focuses on highly selective HTR1D agonists to minimize cardiovascular vasoconstriction risks associated with HTR1B activation while maintaining trigeminal inhibition efficacy. Next-generation development emphasizes biased agonism (G-protein vs β-arrestin pathways) to decouple analgesic effects from vascular side effects. The competitive landscape is also shifting toward "ditans" (5-HT1F agonists) and CGRP pathway inhibitors, yet HTR1D retains value for patients with cardiovascular comorbidities where triptans are contraindicated. As first-generation therapies dominate the generic market, the next wave of R&D is targeting combination strategies (e.g., with CGRP antagonists) and precision medicine based on genetic variants like rs6299.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Agonist | Eli Lilly, Biohaven (Pfizer) | Acute Migraine, Cluster Headache | Calcium Flux & cAMP Assay (Need functional Gαi/o coupled cell lines) |
| Biased Agonist (G-protein selective) | Academic/Preclinical | Migraine with CV Risk | Bioluminescence Resonance Energy Transfer (BRET) assays requiring stable HTR1D expression |
| Dual 1B/1D Antagonist | Preclinical | Neuroprotection | Cross-reactivity Panel (Need HTR1B/HTR1D ortholog set for selectivity profiling) |
| Antibody/Peptide | Emerging Biotech | Refractory Headache | ECD-Fc Binding & Internalization (Need conformationally relevant extracellular domain) |
Live HTR1D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: